Axicabtagene Ciloleucel | Blood Cancers Today

axicabtagene ciloleucel

Study Identifies Most Cost-Effective CAR T-Cell Therapy in Patients with R/R LBCL

Leah SherwoodTransplantation & Cellular Therapy | November 22, 2022

Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...

ZUMA-12 Trial Assesses Axicabtagene Ciloleucel as First-Line Therapy for High-Risk B-Cell Lymphoma

Kerri FitzgeraldAggressive B-Cell Lymphoma | November 14, 2022

The primary analysis of the study was published in Nature Medicine by Sattva S. Neelapu, MD.